Has results × Multiple Myeloma × Bendamustine Hydrochloride × Clear all Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Completed
24 enrolled 13 charts
BEB-2
Phase 2 Completed
120 enrolled 11 charts
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Phase 1/2 Terminated
23 enrolled 13 charts
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Phase 1 Completed
18 enrolled 10 charts
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Phase 1/2 Unknown
56 enrolled 12 charts
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase 1/2 Terminated
32 enrolled 18 charts
OPTIMAL
Phase 2 Completed
31 enrolled 13 charts
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Completed
38 enrolled 18 charts
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
11 enrolled 9 charts
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Phase 1/2 Completed
70 enrolled 11 charts
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Phase 1/2 Completed
43 enrolled 18 charts
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Phase 1/2 Completed
57 enrolled 19 charts
BVRD
Phase 1/2 Terminated
3 enrolled 4 charts
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Phase 2 Terminated
24 enrolled 3 charts
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase 2 Completed
59 enrolled 9 charts
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Completed
40 enrolled 16 charts